Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1369-1380

  Kluth, Martina ^a   Harasimowicz, Silvia ^a   Burkhardt, Lia ^a   Grupp, Katharina ^a   Krohn, Antje ^a   Prien, Kristina ^a   Gjoni, Jovisa ^a   Haß, Thomas ^a   Galal, Rami ^a   Graefen, Markus ^a   Haese, Alexander ^a   Simon, Ronald ^a   Hühne Simon, Julia ^a   Koop, Christina ^a   Korbel, Jan ^b   Weischenfeld, Joachim ^b   Huland, Hartwig ^a   Sauter, Guido ^a   Quaas, Alexander ^a   Wilczak, Waldemar ^a   Tsourlakis, Maria Christina ^a   Minner, Sarah ^a   Schlomm, Thorsten ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

mutation; p53; progression; prostate cancer; protein

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ALLELE; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; RECURRENCE RISK; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

MUTATION; P53; PROGRESSION; PROSTATE CANCER; PROTEIN;

CHROMOSOME ABERRATIONS; GENE SILENCING; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KALLIKREINS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84904056083     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28784     Document Type: Article

References (50)

1. Mao X, Boyd LK, Yanez-Munoz RJ, et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res 2011; 1: 604-17.
2. Hanel W, Marchenko N, Xu S, et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 2013.
3. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-69.
4. Leroy B, Fournier JL, Ishioka C, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 2013; 41: D962-9.
5. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9.
6. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-28.
7. Schlomm T, Iwers L, Kirstein P, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-9.
8. Vergis R, Corbishley CM, Thomas K, et al. Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys 2010; 78: 35-41.
9. Kudahetti S, Fisher G, Ambroisine L, et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 2009; 104: 20-4.
10. Uzoaru I, Rubenstein M, Mirochnik Y, et al. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol 1998; 67: 33-7.
11. Incognito LS, Cazares LH, Schellhammer PF, et al. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. Int J Oncol 2000; 17: 761-9.
12. Agell L, Hernandez S, de Muga S, et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 2008; 21: 1470-8.
13. Bettendorf O, Schmidt H, Staebler A, et al. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer 2008; 47: 565-72.
14. Das K, Lau W, Sivaswaren C, et al. Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study. Clin Genet 2005; 68: 40-7.
15. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906.
16. Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16: 1553-60.
17. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-88.
18. Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a tumor suppressor recurrently targeted by 5q21 deletion and required for ERG rearrangement in prostate cancer. Cancer Res 2013;9:2795-805.
19. Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2-ERG fusions. Mod Pathol 2013; 26: 975-83.
20. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181: 401-12.
21. El Gammal AT, Bruchmann M, Zustin J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16: 56-64.
22. Krohn A, Seidel A, Burkhardt L, et al. Recurrent deletion of 3p13 targets multiple tumor suppressor genes and defines a distinct subgroup of aggressive ERG fusion positive prostate cancers. J Pathol 2013; 23: 130-41.
23. Pillai G, Roberts H, Gatter K, et al. p53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology 2003; 42: 83-7.
24. Osman I, Drobnjak M, Fazzari M, et al. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999; 5: 2082-8.
25. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996; 120: 159-66; discussion 66-7.
26. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60: 1585-94.
27. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-56.
28. Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002; 26: 312-9.
29. Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002; 15: 35-44.
30. Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56: 3091-102.
31. Massenkeil G, Oberhuber H, Hailemariam S, et al. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res 1994; 14: 2785-90.
32. Ano Bom APD, Rangel LP, Costa DCF, et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem 2012; 287: 28152-62.
33. Lu X, Liu DP, Xu Y,. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 2013; 32: 2900-6.
34. Vaughan CA, Singh S, Windle B, et al. Gain-of-function activity of mutant p53 in lung cancer through up-regulation of receptor protein tyrosine kinase Axl. Genes Cancer 2012; 3: 491-502.
35. Berger AH, Knudson AG, Pandolfi PP,. A continuum model for tumour suppression. Nature 2011; 476: 163-9.
36. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-52.
37. Lynch CJ, Milner J,. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006; 25: 3463-70.
38. Maroulakou IG, Shibata MA, Jorcyk CL, et al. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice. Mol Carcinogen 1997; 20: 168-74.
39. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-67.
40. Tyner SD, Choi J, Laucirica R, et al. Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinogen 1999; 24: 197-208.
41. Varley JM, Evans DG, Birch JM,. Li-Fraumeni syndrome- A molecular and clinical review. Brit J Cancer 1997; 76: 1-14.
42. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-53.
43. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-88.
44. Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457: E1; discussion E2-3.
45. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664-78.
46. Meek DW,. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9: 714-23.
47. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
48. Gibson BA, Kraus WL,. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13: 411-24.
49. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3: 117-30.
50. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-25.